Improving progression-free and overall survival in patients with cancer: a potential role for bisphosphonates

Author： Lipton Allan  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.12, Iss.5, 2011-04, pp. : 749-762

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Intermediate clinical endpoints: A bridge between progression-free survival and overall survival in ovarian cancer trials

By Matulonis Ursula A.   Oza Amit M.   Ho Tony W.   Ledermann Jonathan A.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1737-1746

Blackwell Publishing

Access to resources Recommend Favorite

Sorafenib may improve response rate and progression-free survival (PFS) duration in patients with iodine refractory thyroid cancer

By  

Inpharma, Vol. 1, Iss. 1647, 2008-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Addition of bevacizumab to cetuximab with or without irinotecan improves progression-free and overall survival durations

By  

Inpharma, Vol. 1, Iss. 1609, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite

Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Becker Andreas   Eichelberg Christian   Sun Maxine  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1907

Blackwell Publishing

Access to resources Recommend Favorite

Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?

By Halabi Susan   Rini Brian I.   Escudier Bernard   Stadler Walter M.   Small Eric J.  

Cancer, Vol. 121, Iss. 11, 2015-06 ,pp. : 1906-1906

Blackwell Publishing

Access to resources Recommend Favorite